{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T10:25:06Z","timestamp":1794565506023,"version":"4.9.1"},"reference-count":91,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2027,9,16]],"date-time":"2027-09-16T00:00:00Z","timestamp":1821052800000},"content-version":"am","delay-in-days":350,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000027","name":"National Institute on Alcohol Abuse and Alcoholism","doi-asserted-by":"publisher","award":["Y1AA-3009"],"award-info":[{"award-number":["Y1AA-3009"]}],"id":[{"id":"10.13039\/100000027","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000027","name":"National Institute on Alcohol Abuse and Alcoholism","doi-asserted-by":"publisher","award":["ZIAAA000550"],"award-info":[{"award-number":["ZIAAA000550"]}],"id":[{"id":"10.13039\/100000027","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["biologicalpsychiatryjournal.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biological Psychiatry"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.biopsych.2026.03.1002","type":"journal-article","created":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T02:54:47Z","timestamp":1775098487000},"page":"831-839","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Glucagon-Like Peptide-1 Receptor Agonists in Psychiatry: A Pharmacoepidemiological Scoping Review"],"prefix":"10.1016","volume":"100","author":[{"given":"Nora D.","family":"Volkow","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopsych.2026.03.1002_bib1","first-page":"473","article-title":"Pharmacoepidemiology and public health: Understanding the population-level impact of pharmaceutical interventions","volume":"15","author":"Wang","year":"2025","journal-title":"J Clin Exp Pharmacol"},{"key":"10.1016\/j.biopsych.2026.03.1002_bib2","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1038\/sj.clpt.6100258","article-title":"Novel statistical tools for monitoring the safety of marketed drugs","volume":"82","author":"Almenoff","year":"2007","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.biopsych.2026.03.1002_bib3","doi-asserted-by":"crossref","first-page":"385","DOI":"10.2165\/00002018-200629050-00003","article-title":"Under-reporting of adverse drug reactions: A systematic review","volume":"29","author":"Hazell","year":"2006","journal-title":"Drug Saf"},{"key":"10.1016\/j.biopsych.2026.03.1002_bib4","doi-asserted-by":"crossref","first-page":"147","DOI":"10.3390\/ph17020147","article-title":"Glucagon-like peptide-1 receptor agonists and suicidal ideation: Analysis of real-word data collected in the European pharmacovigilance database","volume":"17","author":"Ruggiero","year":"2024","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.biopsych.2026.03.1002_bib5","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.23385","article-title":"Disproportionality analysis from World Health Organization data on semaglutide, liraglutide, and suicidality","volume":"7","author":"Schoretsanitis","year":"2024","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.biopsych.2026.03.1002_bib6","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1002\/(SICI)1521-1878(199808)20:8<642::AID-BIES7>3.0.CO;2-K","article-title":"Glucagon-like peptide-1 (GLP-1): A gut hormone of potential interest in the treatment of diabetes","volume":"20","author":"Ahr\u00e9n","year":"1998","journal-title":"Bioessays"},{"key":"10.1016\/j.biopsych.2026.03.1002_bib7","doi-asserted-by":"crossref","first-page":"669","DOI":"10.3390\/biomedicines11030669","article-title":"Effect of glucagon-like peptide-1 receptor agonists on cardio-metabolic risk factors among obese\/overweight individuals treated with antipsychotic drug classes: An updated systematic review and meta-analysis of randomized controlled trials","volume":"11","author":"Patoulias","year":"2023","journal-title":"Biomedicines"},{"key":"10.1016\/j.biopsych.2026.03.1002_bib8","doi-asserted-by":"crossref","first-page":"355","DOI":"10.3892\/etm.2023.12054","article-title":"Therapeutic management of atypical antipsychotic-related metabolic dysfunctions using GLP-1 receptor agonists: A systematic review","volume":"26","author":"Vasiliu","year":"2023","journal-title":"Exp Ther Med"},{"key":"10.1016\/j.biopsych.2026.03.1002_bib9","doi-asserted-by":"crossref","first-page":"5971","DOI":"10.1111\/dom.16657","article-title":"Association of GLP1-receptor agonist use with liver disease progression, major cardiovascular events, and mortality in people with hepatic steatosis and diabetes","volume":"27","author":"Al Ashi","year":"2025","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.biopsych.2026.03.1002_bib10","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1007\/s40501-024-00331-y","article-title":"The impact of GLP-1 receptor agonists (GLP-1 RAs) on mental health: A systematic review","volume":"11","author":"Tempia Valenta","year":"2024","journal-title":"Curr Treat Options Psych"},{"key":"10.1016\/j.biopsych.2026.03.1002_bib14","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1016\/j.jad.2024.10.062","article-title":"Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and suicidality: A replication study using reports to the World Health Organization pharmacovigilance database (VigiBase\u00ae)","volume":"369","author":"McIntyre","year":"2025","journal-title":"J Affect Disord"},{"key":"10.1016\/j.biopsych.2026.03.1002_bib15","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1080\/14740338.2023.2295397","article-title":"The association between glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and suicidality: Reports to the Food and Drug Administration Adverse Event Reporting System (FAERS)","volume":"23","author":"McIntyre","year":"2024","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.biopsych.2026.03.1002_bib16","doi-asserted-by":"crossref","DOI":"10.1192\/j.eurpsy.2023.2474","article-title":"Postmarket safety profile of suicide\/self-injury for GLP-1 receptor agonist: A real-world pharmacovigilance analysis","volume":"66","author":"Chen","year":"2023","journal-title":"Eur Psychiatry"},{"key":"10.1016\/j.biopsych.2026.03.1002_bib17","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1001\/jamainternmed.2024.4369","article-title":"GLP-1 receptor agonist use and risk of suicide death","volume":"184","author":"Ueda","year":"2024","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.biopsych.2026.03.1002_bib18","doi-asserted-by":"crossref","first-page":"5183","DOI":"10.1111\/dom.15864","article-title":"Association between glucagon-like peptide-1 receptor agonists and risk of suicidality: A comprehensive analysis of the global pharmacovigilance database","volume":"26","author":"Kim","year":"2024","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.biopsych.2026.03.1002_bib19","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-024-75965-2","article-title":"The risk of depression, anxiety, and suicidal behavior in patients with obesity on glucagon like peptide-1 receptor agonist therapy","volume":"14","author":"Kornelius","year":"2024","journal-title":"Sci Rep"},{"key":"10.1016\/j.biopsych.2026.03.1002_bib20","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1038\/s41591-023-02672-2","article-title":"Association of semaglutide with risk of suicidal ideation in a real-world cohort","volume":"30","author":"Wang","year":"2024","journal-title":"Nat Med"},{"key":"10.1016\/j.biopsych.2026.03.1002_bib21","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1001\/jamapediatrics.2024.3812","article-title":"Risk of suicidal ideation or attempts in adolescents with obesity treated with GLP1 receptor agonists","volume":"178","author":"Kerem","year":"2024","journal-title":"JAMA Pediatr"},{"key":"10.1016\/j.biopsych.2026.03.1002_bib22","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2024-080679","article-title":"Glucagon-like peptide-1 receptor agonists and risk of suicidality among patients with type 2 diabetes: Active comparator, new user cohort study","volume":"388","author":"Shapiro","year":"2025","journal-title":"BMJ"},{"key":"10.1016\/j.biopsych.2026.03.1002_bib23","doi-asserted-by":"crossref","DOI":"10.1111\/1753-0407.70151","article-title":"Impact of GLP-1 receptor agonists on suicide behavior: A meta-analysis based on randomized controlled trials","volume":"17","author":"Chen","year":"2025","journal-title":"J Diabetes"},{"key":"10.1016\/j.biopsych.2026.03.1002_bib24","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1001\/jamapsychiatry.2025.0091","article-title":"Suicide and self-harm events with GLP-1 receptor agonists in adults with diabetes or obesity: A systematic review and meta-analysis","volume":"82","author":"Ebrahimi","year":"2025","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.biopsych.2026.03.1002_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2025.103385","article-title":"Exploring potential associations between GLP-1RAs and depressive disorders: A pharmacovigilance study based on FAERS and VigiBase data","volume":"86","author":"Wang","year":"2025","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.biopsych.2026.03.1002_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.jad.2025.119670","article-title":"Depression and suicide\/self-injury signals for weight loss medications: A disproportionality analysis of semaglutide, liraglutide, and tirzepatide in FAERS database","volume":"389","author":"Wang","year":"2025","journal-title":"J Affect Disord"},{"key":"10.1016\/j.biopsych.2026.03.1002_bib27","doi-asserted-by":"crossref","first-page":"891","DOI":"10.2165\/00002018-200730100-00007","article-title":"Impact of safety alerts on measures of disproportionality in spontaneous reporting databases: The notoriety bias","volume":"30","author":"Pariente","year":"2007","journal-title":"Drug Saf"},{"key":"10.1016\/j.biopsych.2026.03.1002_bib28","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1001\/jamainternmed.2024.4346","article-title":"Psychiatric safety of semaglutide for weight management in people without known major psychopathology: Post hoc analysis of the STEP 1, 2, 3, and 5 trials","volume":"184","author":"Wadden","year":"2024","journal-title":"JAMA Intern Med"},{"issue":"suppl 1","key":"10.1016\/j.biopsych.2026.03.1002_bib29","article-title":"OR10-05 improved mental and psychosocial patient-reported outcomes among people with obesity treated with tirzepatide: Results from SURMOUNT-1 study","volume":"7","author":"Poon","year":"2023","journal-title":"J Endocr Soc"},{"key":"10.1016\/j.biopsych.2026.03.1002_bib30","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.jpsychires.2023.05.041","article-title":"Glucagon-like peptide 1 (GLP-1) receptor agonists as a protective factor for incident depression in patients with diabetes mellitus: A systematic review","volume":"164","author":"Cooper","year":"2023","journal-title":"J Psychiatr Res"},{"key":"10.1016\/j.biopsych.2026.03.1002_bib31","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.pcd.2024.05.005","article-title":"Glucagon-like peptide receptor agonists and risk for depression","volume":"18","author":"Tagliapietra","year":"2024","journal-title":"Prim Care Diabetes"},{"key":"10.1016\/j.biopsych.2026.03.1002_bib32","doi-asserted-by":"crossref","first-page":"315","DOI":"10.7326\/ANNALS-24-01347","article-title":"Glucagon-like peptide-1 receptor agonists and risk for depression in older adults with type 2 diabetes: A target trial emulation study","volume":"178","author":"Tang","year":"2025","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.biopsych.2026.03.1002_bib33","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.jagp.2023.08.010","article-title":"The antidepressant effects of GLP-1 receptor agonists: A systematic review and meta-analysis","volume":"32","author":"Chen","year":"2024","journal-title":"Am J Geriatr Psychiatry"},{"key":"10.1016\/j.biopsych.2026.03.1002_bib34","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.euroneuro.2025.08.002","article-title":"Repurposing glucagon-like peptide-1 (GLP-1) receptor agonists for the treatment of depression: A systematic review of preclinical, observational and clinical investigations","volume":"99","author":"Li","year":"2025","journal-title":"Eur Neuropsychopharmacol"},{"key":"10.1016\/j.biopsych.2026.03.1002_bib35","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1002\/wps.21036","article-title":"Metabolic side effects in persons with schizophrenia during mid- to long-term treatment with antipsychotics: A network meta-analysis of randomized controlled trials","volume":"22","author":"Burschinski","year":"2023","journal-title":"World Psychiatry"},{"key":"10.1016\/j.biopsych.2026.03.1002_bib36","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1001\/jamapsychiatry.2025.2332","article-title":"Semaglutide treatment of antipsychotic-treated patients with schizophrenia, prediabetes, and obesity: The HISTORI randomized clinical trial","volume":"82","author":"Ganeshalingam","year":"2025","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.biopsych.2026.03.1002_bib37","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1001\/jamapsychiatry.2017.1220","article-title":"Effect of liraglutide treatment on prediabetes and overweight or obesity in clozapine- or olanzapine-treated patients with schizophrenia spectrum disorder: A randomized clinical trial","volume":"74","author":"Larsen","year":"2017","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.biopsych.2026.03.1002_bib38","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.jad.2025.04.046","article-title":"A double-blind, placebo-controlled trial of exenatide for the treatment of olanzapine-related weight gain in obese and overweight adults","volume":"382","author":"Patino","year":"2025","journal-title":"J Affect Disord"},{"key":"10.1016\/j.biopsych.2026.03.1002_bib39","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1111\/dom.12795","article-title":"Effect of GLP-1 receptor agonist treatment on body weight in obese antipsychotic-treated patients with schizophrenia: A randomized, placebo-controlled trial","volume":"19","author":"Ish\u00f8y","year":"2017","journal-title":"Diabetes Obes Metab"},{"issue":"4","key":"10.1016\/j.biopsych.2026.03.1002_bib40","doi-asserted-by":"crossref","first-page":"sbaf143","DOI":"10.1093\/schbul\/sbaf143","article-title":"Weight loss in veterans with schizophrenia and multimorbidity prescribed semaglutide: Results from a national retrospective cohort study","volume":"52","author":"Browne","year":"2026","journal-title":"Schizophr Bull"},{"key":"10.1016\/j.biopsych.2026.03.1002_bib41","doi-asserted-by":"crossref","first-page":"2544","DOI":"10.1038\/s41366-025-01885-4","article-title":"Weight change from incretin-based weight loss medications across categories of second-generation antipsychotics","volume":"49","author":"Varghese","year":"2025","journal-title":"Int J Obes (Lond)"},{"key":"10.1016\/j.biopsych.2026.03.1002_bib42","doi-asserted-by":"crossref","DOI":"10.1177\/20451253231165169","article-title":"Semaglutide for the treatment of antipsychotic-associated weight gain in patients not responding to metformin - A case series","volume":"13","author":"Prasad","year":"2023","journal-title":"Ther Adv Psychopharmacol"},{"key":"10.1016\/j.biopsych.2026.03.1002_bib43","doi-asserted-by":"crossref","DOI":"10.1016\/j.psychres.2025.116592","article-title":"Efficacy and safety of GLP1-ras compared to SGLT2is and DPP-4is in individuals with schizophrenia and diabetes: A Danish nationwide target-trial emulation study","volume":"351","author":"Jacobsen","year":"2025","journal-title":"Psychiatry Res"},{"key":"10.1016\/j.biopsych.2026.03.1002_bib44","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1111\/dom.13522","article-title":"Glucagon-like peptide-1 receptor agonists for antipsychotic-associated cardio-metabolic risk factors: A systematic review and individual participant data meta-analysis","volume":"21","author":"Siskind","year":"2019","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.biopsych.2026.03.1002_bib45","doi-asserted-by":"crossref","DOI":"10.3389\/fnmol.2021.793004","article-title":"GLP-1 suppresses feeding behaviors and modulates neuronal electrophysiological properties in multiple brain regions","volume":"14","author":"Chen","year":"2021","journal-title":"Front Mol Neurosci"},{"key":"10.1016\/j.biopsych.2026.03.1002_bib46","doi-asserted-by":"crossref","first-page":"5338","DOI":"10.3390\/ijms26115338","article-title":"GLP-1 analogues in the neurobiology of addiction: Translational insights and therapeutic perspectives","volume":"26","author":"Marquez-Meneses","year":"2025","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.biopsych.2026.03.1002_bib47","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1111\/add.16626","article-title":"GLP-1R agonist medications for addiction treatment","volume":"120","author":"Volkow","year":"2025","journal-title":"Addiction"},{"key":"10.1016\/j.biopsych.2026.03.1002_bib48","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-023-48267-2","article-title":"Semaglutide and tirzepatide reduce alcohol consumption in individuals with obesity","volume":"13","author":"Quddos","year":"2023","journal-title":"Sci Rep"},{"key":"10.1016\/j.biopsych.2026.03.1002_bib49","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.23m15068","article-title":"Significant decrease in alcohol use disorder symptoms secondary to semaglutide therapy for weight loss: A case series","volume":"85","author":"Richards","year":"2023","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.biopsych.2026.03.1002_bib50","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1038\/s41591-024-03412-w","article-title":"Mapping the effectiveness and risks of GLP-1 receptor agonists","volume":"31","author":"Xie","year":"2025","journal-title":"Nat Med"},{"key":"10.1016\/j.biopsych.2026.03.1002_bib51","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.neuroimage.2012.08.057","article-title":"Acute alcohol intoxication decreases glucose metabolism but increases acetate uptake in the human brain","volume":"64","author":"Volkow","year":"2013","journal-title":"Neuroimage"},{"key":"10.1016\/j.biopsych.2026.03.1002_bib52","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1111\/bcpt.13776","article-title":"Use of GLP-1 receptor agonists and subsequent risk of alcohol-related events. A nationwide register-based cohort and self-controlled case series study","volume":"131","author":"Wium-Andersen","year":"2022","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"10.1016\/j.biopsych.2026.03.1002_bib53","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1001\/jamapsychiatry.2024.3599","article-title":"Repurposing semaglutide and liraglutide for alcohol use disorder","volume":"82","author":"L\u00e4hteenvuo","year":"2025","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.biopsych.2026.03.1002_bib54","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1111\/add.16679","article-title":"The association between glucose-dependent insulinotropic polypeptide and\/or glucagon-like peptide-1 receptor agonist prescriptions and substance-related outcomes in patients with opioid and alcohol use disorders: A real-world data analysis","volume":"120","author":"Qeadan","year":"2025","journal-title":"Addiction"},{"key":"10.1016\/j.biopsych.2026.03.1002_bib55","doi-asserted-by":"crossref","DOI":"10.1172\/JCI188314","article-title":"Glucagon-like peptide-1 receptor agonists, but not dipeptidyl peptidase-4 inhibitors, reduce alcohol intake","volume":"135","author":"Farokhnia","year":"2025","journal-title":"J Clin Invest"},{"key":"10.1016\/j.biopsych.2026.03.1002_bib56","article-title":"GLP-1 receptor agonists vs alternatives for alcohol use disorder: A multi-target trial emulation","author":"Rodriguez","year":"2025","journal-title":"medRxiv"},{"key":"10.1016\/j.biopsych.2026.03.1002_bib58","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/j.gastha.2024.07.006","article-title":"Cannabinoids block fat-induced incretin release via CB1-dependent and CB1-independent pathways in intestinal epithelium","volume":"3","author":"Perez","year":"2024","journal-title":"Gastro Hep Adv"},{"key":"10.1016\/j.biopsych.2026.03.1002_bib59","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2024.102726","article-title":"12-month neurological and psychiatric outcomes of semaglutide use for type 2 diabetes: A propensity-score matched cohort study","volume":"74","author":"De Giorgi","year":"2024","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.biopsych.2026.03.1002_bib60","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1038\/nn.4540","article-title":"GLP-1 acts on habenular avoidance circuits to control nicotine intake","volume":"20","author":"Tuesta","year":"2017","journal-title":"Nat Neurosci"},{"key":"10.1016\/j.biopsych.2026.03.1002_bib61","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1093\/ntr\/ntab066","article-title":"Exenatide adjunct to nicotine patch facilitates smoking cessation and may reduce post-cessation weight gain: A pilot randomized controlled trial","volume":"23","author":"Yammine","year":"2021","journal-title":"Nicotine Tob Res"},{"key":"10.1016\/j.biopsych.2026.03.1002_bib62","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.101865","article-title":"Effect of dulaglutide in promoting abstinence during smoking cessation: A single-centre, randomized, double-blind, placebo-controlled, parallel group trial","volume":"57","author":"Lengsfeld","year":"2023","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.biopsych.2026.03.1002_bib63","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.7326\/M23-2718","article-title":"Association of semaglutide with tobacco use disorder in patients with type 2 diabetes: Target trial emulation using real-world data","volume":"177","author":"Wang","year":"2024","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.biopsych.2026.03.1002_bib64","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.brainresbull.2022.08.022","article-title":"Dose titration with the glucagon-like peptide-1 agonist, liraglutide, reduces cue- and drug-induced heroin seeking in high drug-taking rats","volume":"189","author":"Evans","year":"2022","journal-title":"Brain Res Bull"},{"key":"10.1016\/j.biopsych.2026.03.1002_bib65","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.brainresbull.2022.08.023","article-title":"Acute treatment with the glucagon-like peptide-1 receptor agonist, liraglutide, reduces cue- and drug-induced fentanyl seeking in rats","volume":"189","author":"Urbanik","year":"2022","journal-title":"Brain Res Bull"},{"key":"10.1016\/j.biopsych.2026.03.1002_bib66","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1097\/FBP.0000000000000685","article-title":"Acute glucagon-like peptide-1 receptor agonist liraglutide prevents cue-, stress-, and drug-induced heroin-seeking in rats","volume":"33","author":"Douton","year":"2022","journal-title":"Behav Pharmacol"},{"key":"10.1016\/j.biopsych.2026.03.1002_bib67","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.35247","article-title":"Semaglutide and opioid overdose risk in patients with type 2 diabetes and opioid use disorder","volume":"7","author":"Wang","year":"2024","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.biopsych.2026.03.1002_bib68","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1002\/oby.70024","article-title":"GLP-1 receptor agonists and substance use disorders in older adults with type 2 diabetes: A target trial emulation","author":"Dai","year":"2026","journal-title":"Obesity (Silver Spring) 34 Suppl 2"},{"key":"10.1016\/j.biopsych.2026.03.1002_bib69","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0069010","article-title":"The glucagon-like peptide 1 analogue, exendin-4, attenuates the rewarding properties of psychostimulant drugs in mice","volume":"8","author":"Egecioglu","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.biopsych.2026.03.1002_bib70","author":"Demirci"},{"key":"10.1016\/j.biopsych.2026.03.1002_bib71","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s13256-025-05049-w","article-title":"Use of semaglutide in a 54-year-old patient with cocaine abuse and weight loss: A case report","volume":"19","author":"Romeo","year":"2025","journal-title":"J Med Case Rep"},{"key":"10.1016\/j.biopsych.2026.03.1002_bib72","doi-asserted-by":"crossref","first-page":"3","DOI":"10.53941\/cna.2025.100003","article-title":"Semaglutide for craving reduction in a cocaine dependent patient: A case report","volume":"1","author":"Sileoni","year":"2025","journal-title":"Clin Neuropsychopharmacol Addict"},{"key":"10.1016\/j.biopsych.2026.03.1002_bib73","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2021.108614","article-title":"Testing the effects of the GLP-1 receptor agonist exenatide on cocaine self-administration and subjective responses in humans with cocaine use disorder","volume":"221","author":"Angarita","year":"2021","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.biopsych.2026.03.1002_bib74","article-title":"GLP-1 receptor agonists: A novel pharmacotherapy for binge eating (binge eating disorder and bulimia nervosa)? A systematic review","volume":"35","author":"Aoun","year":"2024","journal-title":"J Clin Transl Endocrinol"},{"key":"10.1016\/j.biopsych.2026.03.1002_bib75","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1007\/s40519-025-01720-9","article-title":"The impact of glucagon-like peptide-1 (GLP-1) agonists in the treatment of eating disorders: A systematic review and meta-analysis","volume":"30","author":"Radkhah","year":"2025","journal-title":"Eat Weight Disord"},{"key":"10.1016\/j.biopsych.2026.03.1002_bib76","doi-asserted-by":"crossref","DOI":"10.1111\/obr.13709","article-title":"Highway to the danger zone? A cautionary account that GLP-1 receptor agonists may be too effective for unmonitored weight loss","volume":"25","author":"Richards","year":"2024","journal-title":"Obes Rev"},{"key":"10.1016\/j.biopsych.2026.03.1002_bib77","article-title":"Psychiatric adverse events associated with GLP-1 receptor agonists: A real-world pharmacovigilance study based on the FDA Adverse Event Reporting System database","volume":"15","author":"Chen","year":"2024","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.biopsych.2026.03.1002_bib78","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1007\/s11096-025-01943-x","article-title":"Psychiatric adverse events linked to glucagon-like peptide 1 analogues: A disproportionality analysis in American, Canadian and Australian adverse event databases","volume":"47","author":"Katranski","year":"2025","journal-title":"Int J Clin Pharm"},{"key":"10.1016\/j.biopsych.2026.03.1002_bib79","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.clnu.2025.06.011","article-title":"Psychiatric and psychological adverse effects associated with dulaglutide, semaglutide, and liraglutide: A vigibase study","volume":"51","author":"Nishida","year":"2025","journal-title":"Clin Nutr"},{"key":"10.1016\/j.biopsych.2026.03.1002_bib80","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2024.1416985","article-title":"Pharmacovigilance study of GLP-1 receptor agonists for metabolic and nutritional adverse events","volume":"15","author":"He","year":"2024","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.biopsych.2026.03.1002_bib81","doi-asserted-by":"crossref","first-page":"3735","DOI":"10.3390\/nu17233735","article-title":"Beyond weight loss: GLP-1 usage and appetite regulation in the context of eating disorders and psychosocial processes","volume":"17","author":"Krug","year":"2025","journal-title":"Nutrients"},{"key":"10.1016\/j.biopsych.2026.03.1002_bib82","article-title":"Successful treatment of binge eating disorder with the GLP-1 agonist semaglutide: A retrospective cohort study","volume":"7","author":"Richards","year":"2023","journal-title":"Obes Pillars"},{"key":"10.1016\/j.biopsych.2026.03.1002_bib83","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1111\/imj.16499","article-title":"Resolution of symptoms of binge eating disorder associated with semaglutide treatment for obesity and type 1 diabetes","volume":"54","author":"Gong","year":"2024","journal-title":"Intern Med J"},{"key":"10.1016\/j.biopsych.2026.03.1002_bib84","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1093\/ajhp\/zxaf088","article-title":"Dulaglutide use to improve binge eating behaviors in a person with type 2 diabetes and obesity","volume":"82","author":"Innocent","year":"2025","journal-title":"Am J Health Syst Pharm"},{"key":"10.1016\/j.biopsych.2026.03.1002_bib85","article-title":"Semaglutide for treating obesity induced by craniopharyngioma resection: A successful case study","volume":"1","author":"Sciacovelli","year":"2023","journal-title":"JCEM Case Rep"},{"key":"10.1016\/j.biopsych.2026.03.1002_bib86","doi-asserted-by":"crossref","first-page":"4038","DOI":"10.1038\/s41591-025-04035-5","article-title":"Brain activity associated with breakthrough food preoccupation in an individual on tirzepatide","volume":"31","author":"Choi","year":"2025","journal-title":"Nat Med"},{"key":"10.1016\/j.biopsych.2026.03.1002_bib87","doi-asserted-by":"crossref","first-page":"e2","DOI":"10.1192\/bjo.2025.10909","article-title":"Semaglutide-associated worsening of atypical anorexia nervosa in an adolescent girl: Case report","volume":"12","author":"Liekens","year":"2025","journal-title":"BJPsych Open"},{"key":"10.1016\/j.biopsych.2026.03.1002_bib88","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1097\/JCP.0000000000001820","article-title":"Semaglutide misuse in atypical anorexia nervosa-A case report","volume":"44","author":"Guerdjikova","year":"2024","journal-title":"J Clin Psychopharmacol"},{"issue":"suppl 1","key":"10.1016\/j.biopsych.2026.03.1002_bib89","doi-asserted-by":"crossref","first-page":"i300","DOI":"10.1093\/ijnp\/pyae059.533","article-title":"Pharmacovigilance signals of semaglutide and other GLP-1 receptor agonists: An analysis of the Food and Drug Administration (FDA) Adverse Events Reporting System (FAERS) dataset","volume":"28","author":"Chiappini","year":"2025","journal-title":"Int J Neuropsychopharmacol"},{"key":"10.1016\/j.biopsych.2026.03.1002_bib90","series-title":"APA Releases Road Map for the Future of the DSM","year":"2026"},{"key":"10.1016\/j.biopsych.2026.03.1002_bib96","series-title":"Pharmacovigilance Essentials","first-page":"55","article-title":"Databases used in pharmacovigilance across the globe","author":"Bhati","year":"2024"},{"key":"10.1016\/j.biopsych.2026.03.1002_bib97","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1161\/CIRCULATIONAHA.118.038814","article-title":"Use of genetic variants related to antihypertensive drugs to inform on efficacy and side effects","volume":"140","author":"Gill","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.biopsych.2026.03.1002_bib98","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1093\/eurheartj\/eht571","article-title":"Mendelian randomization of blood lipids for coronary heart disease","volume":"36","author":"Holmes","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.biopsych.2026.03.1002_bib99","doi-asserted-by":"crossref","DOI":"10.1016\/j.jad.2025.119509","article-title":"Association of glucagon-like peptide-1 receptor agonists and seven common mental disorders: A drug target and mediation Mendelian randomization","volume":"388","author":"Zhang","year":"2025","journal-title":"J Affect Disord"},{"key":"10.1016\/j.biopsych.2026.03.1002_bib100","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1186\/s12888-025-06914-0","article-title":"Exploring glucagon-like peptide-1 receptor agonists as potential disease-modifying agent in psychiatric and neurodevelopmental conditions: Evidence from a drug target Mendelian randomization","volume":"25","author":"Zhang","year":"2025","journal-title":"BMC Psychiatry"}],"container-title":["Biological Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006322326011327?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006322326011327?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T09:49:35Z","timestamp":1794563375000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006322326011327"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":91,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S0006322326011327"],"URL":"https:\/\/doi.org\/10.1016\/j.biopsych.2026.03.1002","relation":{},"ISSN":["0006-3223"],"issn-type":[{"value":"0006-3223","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Glucagon-Like Peptide-1 Receptor Agonists in Psychiatry: A Pharmacoepidemiological Scoping Review","name":"articletitle","label":"Article Title"},{"value":"Biological Psychiatry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopsych.2026.03.1002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc on behalf of Society of Biological Psychiatry.","name":"copyright","label":"Copyright"}]}}